AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04943601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
Study NCT04395625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct bonding of Orthodontic brackets
Description: Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
Study NCT04395625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect bonding of Orthodontic brackets
Description: Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
Study NCT03457701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
Study NCT01207583 — intervention group
Intervention type: OTHER
Intervention: Non-interventional observational study
Description: Non-interventional observational study
Study NCT03457701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEPO
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
Study NCT03457701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (57Fe)
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
Study NCT03457701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (58Fe)
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
Study NCT01301157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Description: Proper quantity twice a day
Study NCT01301157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Proper quantity twice a day
Study NCT01301157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex
Description: Proper quantity twice a day
Study NCT02790476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters
Description: The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone.
Study NCT03193424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
Study NCT03193424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
Study NCT02102633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib 500 mg orally
Study NCT00768729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
Study NCT00768729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF or Azathioprine
Description: 600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
Study NCT01303575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, STI and Pregnancy Prevention Curriculum
Description: A complete internet-based, It's Your Game...Keep It Real Intervention Program
Study NCT01303575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Curricula
Description: A computer-based, science education program that does not contain elements of sexual health education
Study NCT00885547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii (TW)
Description: 90 mg/d for 6 months
Study NCT00006916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin
Study NCT00006916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ommaya reservoir
Study NCT00006916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tACS
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active tACS
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active boosting
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham boosting
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
Study NCT03756610 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham boosting
Description: Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
Study NCT00832403 — intervention group
Intervention type: OTHER
Intervention: implants of polytetrafluoroethylene in tha nasal fossa
Description: surgical implants of polytetrafluoroethylene in the nasal fossa
Study NCT05618106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: variations of the low FODMAP diet
Description: Cross-over of 3 interventions in IBS patients:~1. Low Polyol diet~2. Low FOS+GOS diet~3. Low FODMAP diet
Study NCT02249546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine + PPI-amoxicillin-clarithromycin
Study NCT02249546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-amoxicillin-clarithromycin
Description: Triple therapy
Study NCT04324814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein
Study NCT00564213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds
Description: Mitomycin 0.02%
Study NCT03742895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg administered BID as two, 150 mg oral tablets.
Study NCT03730259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Tailored Intervention Preparation for Surgery
Description: A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
Study NCT02363504 — intervention group
Intervention type: OTHER
Intervention: 7 Tesla MRI with memory task and non-invasive neurostimulation
Description: This is not an intervention, we investigate the neural mechanisms
Study NCT01085331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Study NCT00753896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 2.0mcg, once weekly
Study NCT02350426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
Study NCT03834831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Coenzyme Q10
Study NCT01085331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Study NCT01085331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
Study NCT02350426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
Study NCT02350426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-GE-180
Description: 18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
Study NCT03251716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine
Description: berberine 300mg TID add-on for berberine adjunctive group
Study NCT00458510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Description: treatment of up to 4 episodes of pain per day
Study NCT02534389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fish oil
Description: 2,4g of EPA + DHA
Study NCT00631046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
Study NCT00631046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
Study NCT03232593 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Study NCT00560391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
Study NCT00560391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
Study NCT00560391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
Study NCT00560391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
Study NCT00560391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
Study NCT01199146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg by mouth per day
Study NCT02664181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given at 3mg/kg by IV every two weeks until progression
Study NCT02664181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at 3mg/kg by IV every two weeks until progression
Study NCT02664181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral decitabine
Description: oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
Study NCT02664181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: Oral THU \~10 mg/kg twice weekly on consecutive days
Study NCT04342819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Sodium-Glucose Like Transporter 2 Inhibitor
Study NCT03948061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
Study NCT02115607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity infusion
Description: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
Study NCT04680559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCBI
Description: The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
Study NCT03834831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Selenium
Study NCT00765804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 with EyeGate® II System
Description: Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
Study NCT00765804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium citrate buffer solution with EyeGate® II System
Description: Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
Study NCT02736344 — intervention group
Intervention type: DEVICE
Intervention: BioNIR Ridaforolimus Eluting Coronary Stent
Study NCT00548145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 2 mg by orally/day Duration: 12 months
Study NCT00548145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
Description: duration: 12 months
Study NCT01053039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
Study NCT01053039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Saline
Description: The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
Study NCT02324816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
Study NCT03137225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
Study NCT03137225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation
Description: Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
Study NCT02402140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Intervention
Description: Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.